These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 34880074

  • 1. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
    Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K, Japanese Study Group of Kidney Disease in Children.
    J Am Soc Nephrol; 2022 Feb; 33(2):401-419. PubMed ID: 34880074
    [Abstract] [Full Text] [Related]

  • 2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K.
    BMC Nephrol; 2018 Nov 01; 19(1):302. PubMed ID: 30382824
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
    Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X, Liu A, Shu Q, Du L.
    Nephrology (Carlton); 2016 Jan 01; 21(1):21-7. PubMed ID: 26697959
    [Abstract] [Full Text] [Related]

  • 4. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
    Lancet; 2014 Oct 04; 384(9950):1273-81. PubMed ID: 24965823
    [Abstract] [Full Text] [Related]

  • 5. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C, Sako M, Kamei K, Ishikura K, Nakamura H, Nakanishi K, Omori T, Nozu K, Iijima K.
    BMC Nephrol; 2019 Aug 02; 20(1):293. PubMed ID: 31375087
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
    Fujinaga S, Hirano D, Nishino T, Umeda C, Watanabe Y, Nakagawa M.
    Pediatr Nephrol; 2019 Nov 02; 34(11):2417-2421. PubMed ID: 31435725
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
    Pediatr Nephrol; 2017 Nov 02; 32(11):2071-2078. PubMed ID: 28664242
    [Abstract] [Full Text] [Related]

  • 8. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
    Basu B, Babu BG, Mahapatra TK.
    Clin Exp Nephrol; 2017 Feb 02; 21(1):143-151. PubMed ID: 27108294
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy of mycophenolate mofetil versus levamisole therapy in frequently relapsing and steroid dependent childhood nephrotic syndrome - A retrospective comparative analysis.
    Sharma S, Kalra S, Shukla S, Sharma P.
    Nephrology (Carlton); 2022 Sep 02; 27(9):758-762. PubMed ID: 35619554
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolate mofetil for sustained remission in nephrotic syndrome.
    Querfeld U, Weber LT.
    Pediatr Nephrol; 2018 Dec 02; 33(12):2253-2265. PubMed ID: 29750317
    [Abstract] [Full Text] [Related]

  • 11. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
    Bagga A, Hari P, Moudgil A, Jordan SC.
    Am J Kidney Dis; 2003 Dec 02; 42(6):1114-20. PubMed ID: 14655181
    [Abstract] [Full Text] [Related]

  • 12. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T.
    Clin Exp Nephrol; 2017 Aug 02; 21(4):671-676. PubMed ID: 27558467
    [Abstract] [Full Text] [Related]

  • 13. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
    Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K.
    Pediatr Nephrol; 2011 Oct 02; 26(10):1823-8. PubMed ID: 21556716
    [Abstract] [Full Text] [Related]

  • 14. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ.
    Health Technol Assess; 2019 May 02; 23(26):1-108. PubMed ID: 31156083
    [Abstract] [Full Text] [Related]

  • 15. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
    Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM.
    Cochrane Database Syst Rev; 2020 Apr 16; 4(4):CD002290. PubMed ID: 32297308
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome.
    Al-Akash S, Al-Makdama A.
    Ann Saudi Med; 2005 Apr 16; 25(5):380-4. PubMed ID: 16270759
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S.
    Pediatr Nephrol; 2016 Jan 16; 31(1):89-95. PubMed ID: 26341251
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate Mofetil as a Rescue Therapy in Frequently Relapsing/Steroid-Dependent Nephrotic Syndrome in Children; Ability to Maintain Remission.
    Seyedzadeh A, Tohidi MR, Rafati M, Seyedzadeh MS, Hookari S.
    Iran J Kidney Dis; 2021 Sep 16; 15(5):364-372. PubMed ID: 34582371
    [Abstract] [Full Text] [Related]

  • 19. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome.
    Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB.
    Pediatr Nephrol; 2003 Aug 16; 18(8):833-7. PubMed ID: 12774223
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group.
    Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R.
    Clin J Am Soc Nephrol; 2006 Nov 16; 1(6):1173-8. PubMed ID: 17699344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.